HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.

Abstract
Molecular and genetic investigations in endometrial carcinogenesis may have prognostic and therapeutic implications. We studied the expression of EGFR, c-Met, PTEN and the mTOR signalling pathway (phospho-AKT/phospho-mTOR/phospho-RPS6) in 69 consecutive tumours and 16 tissue microarrays. We also analysed PIK3CA, K-Ras mutations and microsatellite instability (MSI). We distinguished two groups: group 1 (grade 1 and 2 endometrioid cancers) and group 2 (grade 3 endometrioid and type II clear and serous cell cancers). We hypothesised that these histological groups might have different features. We found that a) survival was higher in group 1 with less aggressive tumours (P⟨0.03); b) EGFR (P=0.01), PTEN and the AKT/mTOR/RPS6 signalling pathway were increased in group 1 versus group 2 (P=0.05 for phospho-mTOR); c) conversely, c-Met was higher (P⟨0.03) in group 2 than in group 1; d) In group 1, EGFR was correlated with c-Met, phospho-mTOR, phospho-RPS6 and the global activity of the phospho-AKT/phospho-mTOR/phospho-RPS6 pathway. In group 2, EGFR was correlated only with the phospho-AKT/phospho-mTOR/phospho-RPS6 pathway, whereas c-Met was correlated with PTEN; e) survival was higher for tumours with more than 50% PTEN-positive cells; f) K-RAS and PIK3CA mutations occurred in 10-12% of the available tumours and MSI in 40.4%, with a loss of MLH1 and PMS2 expression. Our results for endometrial cancers provide the first evidence for a difference in status between groups 1 and 2. The patients may benefit from different targeted treatments, anti-EGFR agents and rapamycin derivatives (anti-mTOR) for group 1 and an anti c-MET/ligand complex for group 2.
AuthorsAnne Thoury, Véronique Descatoire, Larissa Kotelevets, Caroline Kannengiesser, Guylène Bertrand, Nathalie Theou-Anton, Caroline Frey, Catherine Genestie, Eric Raymond, Eric Chastre, Thérèse Lehy, Francine Walker
JournalHistology and histopathology (Histol Histopathol) Vol. 29 Issue 11 Pg. 1455-66 (Nov 2014) ISSN: 1699-5848 [Electronic] Spain
PMID24811063 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Ki-67 Antigen
  • Ligands
  • MTOR protein, human
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human
  • EGFR protein, human
  • ErbB Receptors
  • Proto-Oncogene Proteins c-met
  • TOR Serine-Threonine Kinases
  • PTEN Phosphohydrolase
  • PTEN protein, human
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma (genetics, metabolism)
  • Class I Phosphatidylinositol 3-Kinases
  • DNA Mutational Analysis
  • Endometrial Neoplasms (genetics, metabolism)
  • ErbB Receptors (genetics)
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genes, ras
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen (metabolism)
  • Ligands
  • Microsatellite Instability
  • Microsatellite Repeats (genetics)
  • Middle Aged
  • Mutation
  • PTEN Phosphohydrolase (genetics)
  • Phosphatidylinositol 3-Kinases (genetics)
  • Proto-Oncogene Proteins c-met (genetics)
  • Retrospective Studies
  • TOR Serine-Threonine Kinases (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: